The purpose of this legislation, known as the Alzheimer's Screening and Prevention Act (ASAP Act), is to enhance Medicare coverage for blood-based tests that can detect Alzheimer's disease and related dementias at an early stage. The goal is to improve early detection and potentially lead to better management of these conditions. Key provisions of the legislation include the addition of coverage for specific early detection screening tests for Alzheimer's disease and related dementias under Medicare.